A LinkedIn post from Single Quantum highlights the company’s planned presence at APS March 2026, where it will exhibit and feature an invited talk by Dr. Katyayani Seal. The presentation will focus on a quantum detector system for hybrid time-domain diffuse optics, a technique relevant to non-invasive monitoring of blood flow and oxygen saturation.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to the post, the application combines time-domain near-infrared spectroscopy and time-domain diffuse correlation spectroscopy, which demand detectors with high near-infrared quantum efficiency, strong temporal resolution, and low dark count rates. The company suggests its superconducting nanowire single-photon detectors (SNSPDs) address these requirements, positioning its technology as a potential enabler for advanced bio-medical diagnostics.
For investors, the emphasis on bio-medical use cases may indicate Single Quantum’s intent to expand beyond traditional quantum and photonics research markets into healthcare-related applications. If the technology gains traction in medical imaging or monitoring, it could broaden the firm’s addressable market and diversify revenue streams over time.
Participation as an invited speaker at a major physics conference also underscores Single Quantum’s visibility within the scientific community, which can support collaboration opportunities and future commercial partnerships. While the post is promotional in nature, it points to continued R&D engagement and potential long-term demand drivers for high-performance single-photon detection in life-science and clinical settings.